University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center · US
Area of research
Hematology · Genetics
Research interest
Research interests include Acute Myeloid Leukemia Research, Acute Lymphoblastic Leukemia research, Chronic Myeloid Leukemia Treatments, and Myeloproliferative Neoplasms: Diagnosis and Treatment.
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed <i>NPM1</i> -Mutated or <i>KMT2A</i> -Rearranged AML
Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial
Revumenib in combination with intensive induction and consolidation for newly diagnosed patients with NPM1-mutated or KMT2A-rearranged Acute Myeloid Leukemia: Preliminary results from the Phase 1b etctn 10596 study
Beat-AML 2024 ELN–refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy
Entospletinib with decitabine in acute myeloid leukemia with mutant <i>TP53</i> or complex karyotype: A phase 2 substudy of the Beat AML Master Trial
Pevonedistat with azacitidine in older patients with <i>TP53</i>-mutated AML: a phase 2 study with laboratory correlates
B cell-mediated regulatory mechanisms control tumor-promoting intestinal inflammation
Admission screening and cohort care decrease carbapenem resistant enterobacteriaceae in Vietnamese pediatric ICU’s
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents – A Potential Therapy for Cancer